Nachrichten zur Syndax Pharmaceuticals Inc. Aktie

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.…

Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials By Investing.com

Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials…

Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript

…

Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Syndax Pharmaceuticals (SNDX) and Hims & Hers Health (HIMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcellx Inc…

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript

…

Movers & Shakers: SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks

Shares of SmileDirectClub, Syndax Pharmaceuticals, AMC and Chinese automakers were most active ahead of Mondays market open.…

Biggest stock movers today: Syndax Pharmaceuticals, Coinbase Global and more

…

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

– Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the…

Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 1.697.810$

Meury, William - Aufsichtsrat - Tag der Transaktion: 2023-08-02...…

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

WALTHAM, Mass., July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of…

Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End

Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients…

Syndax, Incyte Announce Positive Topline Results From AGAVE-201 Trial Of Axatilimab

WASHINGTON (dpa-AFX) - Syndax Pharmaceuticals Inc. (SNDX) and Incyte Corporation (INCY) announced on Monday positive topline data from their AGAVE-201…

Syndax Shares Rise Premarket on Graft-Vs-Host Study Success >SNDX

Syndax Shares Rise Premarket on Graft-Vs-Host Study Success >SNDX...…

Form 8-K Syndax Pharmaceuticals For: Jul 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose…

Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 1.078.068$

Morrison, Briggs - Aufsichtsrat - Tag der Transaktion: 2023-07-10...…

Barclays bullish on Biomea, Replimune, Syndax, Iovance for 2H 2023

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Syndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

– Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data…

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

WALTHAM, Mass., May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline…

Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 1.032.237$

Morrison, Briggs - Aufsichtsrat - Tag der Transaktion: 2023-04-10...…

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $20.10, marking a -0.94% move from the previous day....…

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

Syndax Pharmaceuticals (SNDX) closed at $20.91 in the latest trading session, marking a -0.99% move from the prior day....…

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer -…

Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $21.94, moving +1.72% from the previous trading session....…

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $23.07, marking a -0.26% move from the previous day....…

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.30, moving -1.24% from the previous trading session....…

Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know

Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.58, moving +0.71% from the previous trading session....…

Expert Ratings for Syndax Pharmaceuticals

Latest Ratings for SNDX DateFirmActionFromTo Feb 2022Goldman SachsInitiates Coverage OnBuy Oct 2021Morgan StanleyMaintainsEqual-Weight May 2021CitigroupInitiates Coverage OnBuy …

Syndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

– Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – –Topline data from the pivotal…

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders…

Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know

Syndax Pharmaceuticals (SNDX) closed at $25.64 in the latest trading session, marking a -1.99% move from the prior day....…

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

WALTHAM, Mass., Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline…

dpa-AFX ProFeed